Table 2.

Patient characteristics for US Department of Veterans Affairs

Baseline: calendar 2013	Baseline		Follow-up
Follow-up: Dec 2015–Dec 2016	N	%	N	%
	3608	100%	3008	100%
Age
< 18 years	0	0.0%	0	0.0%
18–34 years	405	11.2%	308	10.2%
35–44 years	391	10.8%	344	11.4%
45–54 years	890	24.7%	545	18.1%
55–64 years	1431	39.7%	1128	37.5%
65–74 years	425	11.8%	612	20.3%
≥ 75 years	66	1.8%	71	2.4%
< 65 years	3117	86.4%	2325	77.3%
≥ 65 years	491	13.6%	683	22.7%
Median	55.7		57.2
Mean (sd)	53.4 (12.0)		55.0 (12.9)
Gender
Male	3286	91.1%	2740	91.1%
Female	322	8.9%	268	8.9%
Diagnoses*
Schizophrenia only	1146	31.8%	876	29.1%
Bipolar disorder only	234	6.5%	290	9.6%
Schizophrenia and bipolar disorder	2136	59.2%	1655	55.0%
Neither diagnosis	92	2.5%	187	6.2%
Race
White	1973	54.7%	1677	55.8%
Black	1361	37.7%	1097	36.5%
Asian	34	0.9%	32	1.1%
Native Hawaiian or Pacific Islander	40	1.1%	38	1.3%
American Indian or Alaskan native	33	0.9%	25	0.8%
Unknown	167	4.6%	139	4.6%
Ethnicity
Hispanic	291	8.1%	218	7.2%
Unknown	3317	91.9%	2790	92.8%
Census region**
Northeast	595	16.5%	468	15.6%
Midwest	757	21.0%	669	22.2%
South	1582	43.8%	1365	45.4%
West	573	15.9%	438	14.6%
US Territory	101	2.8%	68	2.3%

*Schizophrenia defined as ICD9 diagnosis codes 295.xx and v11.0. Bipolar defined as ICD9 diagnosis codes 296.xx except for 296.90 and 296.99. All codes must have occurred on or before the date of the first administration of Risperdal^® CONSTA^® in the study period.

**Census region defined based on the zip code of where care was provided during the first administration of Risperdal^® CONSTA^® in the study period